Merck KGaA’s agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Acquirers want firms with strong organic growth and next-generation leaders in place.
Most of the opportunities lie with the biggest firms, which have the deepest pockets, but Cerulli sees mergers up and down the AUM spectrum.
The issue isn’t the number. It’s the lens being used to arrive at it.
Bolloré Group, which holds 40% voting rights in Universal Music, has given a thumbs-down to a $65 billion takeover bid.
GameStop CEO Ryan Cohen is sidestepping questions about how much a proposed takeover of eBay — for $56 billion — would benefit stockholders.
The year’s mergers and acquisitions are off to the fastest start ever, and the size of firms being bought is trending upward.
The key patent protections on Keytruda, Merck’s immunotherapy treatment that outsold all other prescription drugs last year, ends in 2028.
A record year for deals highlights the succession challenges RIAs are struggling to overcome.
Standout deals included Union Pacific’s $88 billion purchase of Norfolk Southern and the $56.6 billion deal to take Electronic Arts private.
Some products don’t have the capital to get off the ground. Larger ETF issuers can fix that.
PE will continue to dominate, but medium-sized sellers may fill in the gaps.
Earlier this month, Exact reported a record $851 million in third-quarter revenue, which included $666 million from its screening business.
Goldman Sachs’ share price, up 35% so far year-to-date, set a record high closing price of $838.97 last week.
Sub-acquisitions made up 31% of all RIA M&A activity in 2025 amid rampant private equity investment in the industry.
The acquisition is the latest, and largest,example of mega-firms making moves to buy out competitors in a rapidly consolidating industry.